Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Indaptus Therapeutics ( (INDP) ).
On June 12 and June 30, 2025, Indaptus Therapeutics raised a total of $5.7 million through a private placement of convertible promissory notes and warrants. The funds will be used for research and development, including a Phase 1b/2 clinical trial, and general corporate purposes. The notes, which bear a 6% annual interest rate, will mature on July 28, 2026, and can be converted into common stock. Paulson Investment Company, LLC served as the exclusive placement agent for the offering.
The most recent analyst rating on (INDP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.
Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a clinical stage biotechnology company focused on developing innovative treatments for cancer and viral infections.
Average Trading Volume: 235,114
Technical Sentiment Signal: Sell
Current Market Cap: $6.67M
Learn more about INDP stock on TipRanks’ Stock Analysis page.